Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution
- 10 November 2016
- journal article
- clinical trial
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 22 (2) , 244-249
Abstract
Recent approval of molecular-targeted agents has contributed to improving the therapeutic outcomes of advanced cancer patients. However, they result in unusual adverse events that rarely occur with cytotoxic agents, such as hypertension, hypomagnesemia, and an acne-like rash. Although hypophosphatemia can be induced by various agents, some kinds of molecular-targeted agents are known to induce it. In addition, cancer survivors may be at a risk of hypophosphatemia. One hundred and seventy patients, who visited the Department of Clinical Oncology at Akita University from 1 April 2014 to 31 August 2016 were enrolled in this study after providing informed consent. Serum inorganic phosphorus levels were examined along with other routine clinical examinations. Correlation between the serum inorganic phosphorus level and other clinical data were also analyzed. Grade ≥2 severe hypophosphatemia (<2.5 mg/dL of phosphorus) was detected in 49.4% of patients, and grade ≥3 (<2.0 mg/dL of phosphorus) was observed in 22.9% patients. These results indicated that the presence of bone metastasis (p < 0.001), history of bone-modifying agents (p < 0.001) and molecular-targeted drugs (p = 0.001), and time from the date of the first visit to the date of minimum serum phosphorus level (p < 0.001) might correlate with hypophosphatemia. Multivariate logistic regression analysis showed that disease duration might be a risk factor (p = 0.0466). As hypophosphatemia can be induced by various factors in advanced cancer patients, the serum phosphorus level of cancer patients at risk should be cautiously examined.Keywords
Funding Information
- Department account fund
This publication has 25 references indexed in Scilit:
- Incidence and aetiology of renal phosphate loss in patients with hypophosphatemia in the intensive care unitIntensive Care Medicine, 2013
- Tumor-induced osteomalaciaEndocrine-Related Cancer, 2011
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic reviewAnnals of Oncology, 2009
- SERUM PHOSPHATE AND SYMPATHETIC TONE IN MILD ESSENTIAL HYPERTENSIONActa Medica Scandinavica, 2009
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Altered Bone and Mineral Metabolism in Patients Receiving Imatinib MesylateNew England Journal of Medicine, 2006
- Treatment of electrolyte disorders in adult patients in the intensive care unitAmerican Journal of Health-System Pharmacy, 2005
- Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral MetabolismJournal of Bone and Mineral Research, 2002
- Hypophosphataemia: A dangerous disorderNutrition, 1996